Long non-coding RNA zinc finger antisense 1 functions as an oncogene in acute promyelocytic leukemia cells.

In conclusion, these data indicate that ZFAS1 may serve as an oncogene in APL and may thus be a useful target for future clinical management. PMID: 31807158 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

ConclusionsOur results demonstrate that the incidence of GVHD after daratumumab is low and did not result in increased exacerbation of GVHD in patients with prior history of GVHD.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionT2B2F is associated with a higher incidence of acute GVHD compared to T1B2F. These results suggest that a lower dose-intensity of thiotepa and busulfan in the TBF regimen may yield better results in AML patients in complete remission.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewThis review highlights the importance of the Bcl-2 family members in lymphoma cell survival and discusses the approaches to modulate their function, directly or indirectly, to advance lymphoma therapeutics.Recent FindingsThe balance of cell death versus survival is ultimately leveraged at the mitochondria. Mitochondrial outer membrane permeabilization (MOMP) is the critical event that governs the release of pro-apoptotic molecules from the intermembrane mitochondrial space. MOMP is achieved through the coordinated actions of pro- and anti-apoptotic Bcl-2 family member proteins. Recognition of funct...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
This study suggested that a lower dose-intensity of thiotepa and busulfan (5 mg/kg thiotepa and 2 days of iv busulfan at 6.4 mg/kg (T1B2F) in the TBF regimen may yield better outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Authors: Vučićević Boras V, Vidović Juras D, Aurer I, Bašić-Kinda S, Mikulić M Abstract A 40-year-old female patient was admitted to the Department of Oral Medicine due to oral ulcerations. Oral ulcerations were present on vestibular mucosa above teeth 21, 22, 25 and 26 and were 1 cm in diameter, and also around teeth 45 and 46. The patient had prolonged neutropenia due to therapy-related myelodysplastic syndrome that progressed to therapy-related acute myeloid leukemia. Initially, the patient was successfully treated with polychemotherapy for non-Hodgkin lymphoma. Unfortunately, many toxic complicatio...
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
Chimeric antigen receptor T cell (CAR-T cell) therapy has become a promising treatment for children with acute lymphoblastic leukaemia (ALL) and Non-Hodgkin lymphoma (NHL). Cytokine release syndrome (CRS) and Immune effector cell associated neurotoxicity syndrome (ICANS) are well-documented serious side-effects of CAR-T cell therapy, and early recognition, intervention and aggressive supportive therapy is paramount.Tociluzimab is the mainstay of treatment for moderate to severe CRS, with early administration essential.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 601 Source Type: research
CD19 directed chimeric antigen receptor T cell (CART19) therapy has shown remarkable activity in B cell lymphoma and acute lymphoblastic leukemia (ALL). With the emergence of therapeutic anti CD19 antibodies for the treatment of B cell malignancies, it remains to be elucidated whether such antibodies would interfere with the ability of CART19 to exert their antitumor effect in a subsequent therapy.Tafasitamab is an Fc enhanced humanized anti CD19 monoclonal antibody which mediates antibody dependent cellular toxicity (ADCC), antibody dependent cellular phagocytosis and direct cytotoxicity.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 332 Source Type: research
CART-cell therapy is associated with dramatic efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma and B-acute lymphoblastic leukemia. However, the efficacy of CART therapy is limited by potentially fatal toxicities including cytokine release syndrome (CRS) and neurotoxicity. Increasingly, emerging reports have suggested the potential for significant hemodynamic collapse following CART therapy. Yet, whether the occurrence of these hemodynamic shifts or any other cardiovascular disease (CVD) events have bearing on clinical outcomes after CART initiation is unknown.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 407 Source Type: research
Risk stratification is a critical step when considering allogeneic hematopoietic stem cell transplantation (HSCT). While Lactate dehydrogenase (LDH) is a readily available biomarker with a prognostic role in the front-line therapy setting of hematological malignancies, its ’ role in the pretransplantation setting is undefined.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 152 Source Type: research
Conditions:   Haematological Malignancy;   Leukemia, Acute;   Lymphoma;   Myeloma Multiple;   Blood Cancer;   Quality of Life Intervention:   Other: WHODAS 2.0 Questionnaire Sponsor:   University of Malaya Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Cancer & Oncology | Leukemia | Lymphoma | Study | Zinc